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Objective: To describe effects of HAART on high-risk human papillomavirus (HPV)
antibody response in HIV-positive MSM and the meaning of this response for sub-
sequent HPV-related cancer risk.
Design: Prospective seroepidemiological study of 281 HIV-positive MSM initiating
HAART between 1995 and 2004 in the Swiss HIV Cohort Study.
Methods: For each individual, two serum samples, one at HAART initiation
(pre-HAART) and another 24 months later (post-HAART), were tested for L1 antibodies
to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well as HPV16-E6 antibodies, using
a multiplex serology assay. Identification of HPV-related cancer included data
linkage with Swiss cancer registries.
Results: Pre-HAART, 45.2% were seropositive for any high-risk HPV-L1 and 32.4% for
HPV16-L1. Sexual intercourse during the last 6 months was the only evaluated factor
associated with L1 seropositivity pre-HAART. Seropositivity increased post-HAART to
60.5% for any high-risk HPV-L1 [prevalence ratio versus pre-HAART¼1.34, 95%
confidence interval (CI) 1.14–1.57] and 48.0% for HPV16-L1 (prevalence ratio
versus pre-HAART¼1.48, 95% CI 1.20–1.83), and seroconversion was significantly
associated with both lower CD4þ cell count and CD4þ/CD8þ ratio (P<0.01). Only one
individual was HPV16-E6-seropositive pre-HAART, but two more seroconverted
post-HAART. Anal cancer incidence among the three HPV16-E6-positives post-HAART
was significantly increased compared with HPV16-E6-negatives (incidence rate
ratio¼63.1, 95% CI 1.1–1211).
Conclusion: HAART-related immune reconstitution increases HPV-specific antibody
responses, which may discriminate future anal cancer risk in this high-risk population.
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Introduction
HIV-positive MSM have a high burden of anal high-risk
human papillomavirus (HPV) infection [1]. Con-
sequently, they also suffer a high incidence of anal cancer
[1], for which persistent anal high-risk HPV infection,
predominantly HPV16 [2], is the major cause. In the era
of prolonged survival due to HAART, anal cancer
incidence in HIV-positive MSM has reached more than
100 cases per 100 000 person-years [3,4].
Antibodies to high-risk HPV L1 protein are considered as
markers of cumulative HPV exposure. However, L1
seroconversion does not always occur following natural
HPV infection, and seroconversion rates in men may
differ by the anatomical site of HPV infection [5,6]. There
have been relatively few studies that have evaluated HPV
L1 seropositivity in HIV-positive MSM [6–9], and the
association between anal high-risk HPV infection and the
detection of HPV-L1 antibodies is not clear in this
population [6].
Antibodies against HPV E6 protein, on the other hand,
have been shown to be highly specific markers for HPV-
related cancer [10–16]. However, although HPV16-E6
is a highly sensitive marker for oropharyngeal cancer
and can be consistently detected many years before
cancer diagnosis [14,16], the picture is less clear for
anal and cervical cancer [11,13,15] and even less so in
HIV-positive persons [10,12].
To our knowledge, there are no studies evaluating the
specific effects of HAART immune reconstitution on
HPV antibody responses, nor the meaning of these
responses for long-term HPV-related cancer risk, which
is important to prevent in this high-risk population.
Hence, this study used a multiplex HPV serology method
based on a glutathione S-transferase (GST) capture
immunosorbent assay [17] to describe HPV-L1 and HPV-
E6 antibodies pre and post-HAARTamong a large sample
of HIV-positive MSM [18], who were also followed up
for cancer [3], within the framework of the Swiss HIV
Cohort Study (SHCS).
Methods
Patients were participants in the SHCS, an ongoing study
that has been enrolling persons infected with HIV since
1988 from five large university hospitals, two large
cantonal hospitals, affiliated regional hospitals and private
practitioners in Switzerland (www.shcs.ch). Detailed
information on disease, laboratory tests and HIV-related
treatments were collected at enrolment and at each
6-month follow-up visit [19].
A total of 1624 MSM initiated HAART between
November 1995 and June 2004 while under active
follow-up in the SHCS. We excluded 878 patients with
prior use of any antiretroviral therapy. From this group,
we identified 281 MSM who had serum samples available
within 1 month before (pre-HAART) and 21–27 months
after (post-HAART) HAART initiation [18].
Markers of immunodeficiency (CD4þ and CD8þ cell
counts, CD4þ/CD8þ ratio, HIV viral load), AIDS status
and tobacco consumption were extracted from the SHCS
database. Questions on sexual intercourse during the
last 6 months were asked at follow-up visits after April
2000 only. Individuals diagnosed with HPV-related
cancer cases from HAART initiation until May 2016
were identified in the SHCS database and/or through
record linkage with eight Swiss cancer registries [3,20].
Antibodies were tested at the German Cancer Research
Center, Heidelberg, Germany, using a multiplex HPV
serology assay based on a GST capture ELISA [21,22]
combined with fluorescence-labeled polystyrene beads
(SeroMAP Microspheres; Luminex Corp., Austin, Texas,
USA) [17,23]. Viral antigens were expressed in Escherichia
coli as double fusion proteins with N-terminal GST and a
C-terminal peptide (tag) derived from the large T-antigen
of simian virus 40. Glutathione-casein was coupled
to internally fluorescence-labeled polystyrene beads, and
GST-fusion proteins were affinity purified on the beads
directly in a one-step in-situ procedure. The differently
labeled beads carrying different antigens were then mixed
and incubated with human serum that had been
diluted 1 : 100 in blocking buffer. Antibodies bound to
the beads were then stained with biotinylated antihuman
immunoglobulin followed by the fluorescent reporter
conjugate streptavidin-R-phycoerythrin. A Luminex
analyzer was used to quantify the antibodies bound to
antigens on beads and to identify the antigen by bead
color. Antibody quantity was determined as the median
R-phycoerythrin fluorescence intensity (MFI) from at
least 100 beads of the same internal color.
MFI values were dichotomized as antibody positive
or negative. Cutoff values for HPV16, 18, 31, 33, 35, 45,
53 and 58 L1 were predetermined independently for each
antibody by analyzing MFI values obtained from Korean
HPV-DNA-negative virgin women using the algorithm
of five SDs after exclusion of outliers [24]. Cutoff MFI
values were defined at 1000 for HPV16-E6 [16,25], and
800 and 400 for HPV6 and HPV11 L1 [26]. For any high-
risk HPV-L1, seropositivity was defined as positive for at
least one HPV type among HPV16, 18, 31, 33, 35, 45, 53
and 58.
Seroprevalence of HPV antibodies was calculated for
strata of age, HIV viral load, CD4þ and CD8þ cell
counts, and CD4þ/CD8þ ratio at HAART initiation.
Differences between strata were compared by x2 test or
Cochran–Armitage trend test. At 24-month follow-up,
changes in seropositivity for HPV antibodies were
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evaluated by crude prevalence ratios and corresponding
95% confidence intervals (CIs).
Factors associated with seroconversion were investigated in
patients seronegative at HAART initiation, by calculating
crude odds ratio (OR) of seroconversion and correspond-
ing 95% CI according to baseline characteristics. For any
high-risk HPV-L1, seronegativity at HAART initiation
was defined as negative for at least one HPV type among
HPV16, 18, 31, 33, 35, 45, 53 and 58.
Type-specific mean MFI values at HAART initiation and
at 24-month follow-up were compared among all 281
MSM (irrespective of being seronegative/positive) using
Wilcoxon signed-rank sum test and were additionally
compared across strata of CD4þ at HAART initiation.
For anal cancer incidence rate analyses according to post-
HAART serology result, calculation of person-years at risk
began at the date of post-HAART serology and ended on
the date of last SHCS follow-up, anal cancer or death,
whichever was earliest. Incidence rate ratios and corre-
sponding 95% CI were calculated using exact estimates.
Results
Patient characteristics
Of the 281 included MSM, mean age was 40.8 years
(range 19.6–73.4) and 56 (19.9%) had history of AIDS at
HAART initiation (Table 1). At HAART initiation,
mean CD4þ cell count was 240 cells/ml (median 194,
range 2–1037) and mean viral load 390 000 copies/ml
(median 100 000, range 0–8750 000). Post-HAART,
mean CD4þ was 504 cells/ml (median 444, range 28–
1829) and mean viral load 20 000 copies/ml (median 0,
range 0–2300 000). Table 1 also shows associations of
selected characteristics with HPV16-L1 and high-risk
HPV-L1 seropositivity pre-HAART, of which only
sexual intercourse during the last 6 months was
statistically significant (P¼ 0.01 and 0.04, respectively).
Human papillomavirus antibody seropositivity at
date of HAART initiation (pre-HAART)
Pre-HAART, 91 (32.4%) participants were HPV16-L1-
seropositive (Table 2). Seropositivity for other high-risk
HPV types ranged from 7.8% (HPV58) to 17.8%
(HPV31), and 127 (45.2%) were positive for at least
one high-risk HPV type among HPV16, 18, 31, 33, 35,
45, 52 and 58 (Table 2). Seropositivity of HPV6 and
HPV11 L1 were 40.2 and 29.2%, respectively (Table 2).
Only one participant (0.4%) was positive for HPV16-E6
antibody pre-HAART.
HAART-related changes in human
papillomavirus antibody seropositivity
Post-HAART, seropositivity of all evaluated HPV
antibodies increased (Table 2). A total of 135 (48.0%)
participants were HPV16-L1-seropositive, corresponding
to a prevalence ratio of 1.48 (95% CI 1.20–1.83)
compared with pre-HAART. Post-HAART seropositiv-
ity for other high-risk HPV types ranged from 14.2%
(HPV58) to 34.5% (HPV31), and 170 (60.5%) were
seropositive for at least one high-risk HPV type.
Prevalence ratios for high-risk HPV-L1 seropositivity
post-HAART versus pre-HAART ranged from 1.64
(1.17–2.29) for HPV35 to 2.17 (1.51–3.13) for HPV18.
Seroprevalence was 53.0% for HPV6 [prevalence
ratio¼ 1.32 (1.10–1.58)] and 45.6% for HPV11 [preva-
lence ratio¼ 1.32 (1.10–1.58)].
The one HPV16-E6-seropositive patient pre-HAART
remained seropositive post-HAART, and two more
individuals seroconverted, resulting in a total of three
seropositive (1.1%) post-HAART [prevalence
ratio¼ 3.00 (0.31–28.7)].
Factors associated with seroconversion are described in
Table 3. Among participants HPV16-seronegative pre-
HAART, seroconversion for HPV16-L1 was associated
with low CD4þ cell count [OR¼ 5.28 (1.88–14.8) for
CD4þ <50 versus 350 cells/ml] and low CD4þ/CD8þ
ratio [OR¼ 6.56 (1.98–21.71) for CD4þ/CD8þ ratio
<0.10 versus 0.5] at HAART initiation. Results were
consistent for seroconversion for any high-risk HPV-L1
(Table 3) and were statistically significant for certain
individual types: low CD4þ cell count with seroconver-
sion of HPV31, 33 and 52 and low CD4þ/CD8þ ratio
with seroconversion of HPV31, 33, 35, 45 and 52 (data
not shown).
Changes in human papillomavirus antibody titers
Between pre-HAART and post-HAART, mean MFI
values (a semiquantitative measure of antibody titers)
increased for all evaluated HPV-L1 antibodies (Fig. 1a)
and were statistically significant for all high-risk HPV
types. Mean MFI values for HPV16-L1 increased from
600 to 950, and increases were greatest for participants
with CD4þ cell count less than 50 cells/ml (Fig. 1b).
Incidence of human papillomavirus–related
cancer
The 281 included MSM were actively followed up in the
SHCS for a total of 3771 person-years following HAART
initiation, including 558 person-years before and 3213
person-years after the date of post-HAART serology. Five
incident anal (and no oropharyngeal or penile) cancers
were diagnosed during this time, corresponding to an
overall anal cancer incidence rate of 132/100 000 person-
years, of which two were diagnosed before and two after
the date of post-HAART serology.
Associations between HPV16 serology status post-
HAART (by which time many participants had
seroconverted) and anal cancer incidence are shown in
Table 4. Anal cancer incidence was 0/100 000 person-
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years for post-HAART HPV16-L1 seronegatives versus
196/100 000 person-years for seropositives, correspond-
ing to a nonsignificant incidence rate ratio of1 (95% CI
0.5–1) and 63/100 000 person-years for HPV16-E6
seronegatives versus 3956/100 000 person-years in
seropositives, corresponding to a statistically significant
incidence rate ratio of 63.1 (95% CI 1.1–1211) (Table 4).
The participant who was HPV16-E6-seropositive both
pre-HAART (MFI¼ 1408) and post-HAART
(MFI¼ 1916) had not developed anal cancer by 2016,
15 years after post-HAART serology date. Of the two
participants that seroconverted for HPV16-E6 post-
HAART, one died 7 months later following a diagnosis of
lymphoma (pre-HAART MFI¼ 63; post-HAART
MFI¼ 10 909), and the other developed anal cancer
9 years later (pre-HAART MFI¼ 10; post-HAART
MFI¼ 2382).
Discussion
In a cohort of HIV-infected MSM, we were able to
describe, for the first time to our knowledge, that
HAART is associated with seroconversion and increasing
titers of HPVantibodies. In this high-risk population, for
whom approximately half were already seropositive for at
least one high-risk HPV type before HAART, another
fifth seroconverted to high-risk HPV-L1 in the 2 years
following HAART initiation. Those with the lowest
CD4þ cell count and CD4þ/CD8þ ratio at HAART
initiation were the most likely to seroconvert, suggesting
that HAART-related immune reconstitution contributes
to revealing a detectable immune response to HPV. This
was apparent even for HPV16-E6 antibodies, for which
two out of three seropositive cases were detected only
post-HAART. Furthermore, although numbers of cancer
cases were small, HAART-related seroconversion seemed
564 AIDS 2017, Vol 31 No 4
Table 1. Human papillomavirus antibody seropositivity among 281 MSM, overall and by selected characteristics, at HAART initiation.
HPV16-L1 Any HR-HPV-L1a
n n (%) Pb n (%) Pb
Age (years)
45 81 28 (34.6) 40 (49.4)
35–44 104 38 (36.5) 52 (50.0)
<35 95 25 (26.3) 0.22 35 (36.8) 0.09
Tobacco
Ever 159 46 (28.9) 65 (40.9)
Never 118 43 (36.4) 0.19 60 (50.9) 0.10
History of AIDS
Yes 225 76 (33.8) 104 (46.2)
No 56 15 (26.8) 0.32 23 (41.1) 0.49
Sexual intercourse in the last 6 monthsc
None 21 5 (23.8) 8 (38.1)
Steady partner only 20 5 (25.0) 10 (50.0)
Occasional partner(s) only 21 9 (42.9) 13 (61.9)
Steady and occasional partner(s) 14 9 (64.3) 0.01 10 (71.4) 0.04
HIV viral load (copies/ml)
<10000 38 13 (34.2) 14 (36.9)
10 000–99999 99 28 (28.3) 44 (44.4)
100000–499999 90 29 (32.2) 44 (48.9)
500000 46 20 (43.5) 0.24 23 (50.0) 0.19
CD4þ cell count (cells/ml)
350 68 22 (32.4) 27 (39.7)
200–350 71 24 (33.8) 34 (47.9)
50–199 93 33 (35.9) 48 (51.6)
<50 49 12 (24.5) 0.55 18 (36.7) 0.87
CD8þ cell count (cells/ml)
1000 89 35 (39.3) 45 (50.6)
750–999 58 14 (24.1) 18 (31.0)
500–749 66 21 (31.8) 34 (51.5)
<500 68 21 (30.9) 0.35 30 (44.1) 0.83
CD4þ/CD8þ ratio
0.5 47 13 (27.7) 17 (36.2)
0.25–0.49 80 28 (35.0) 39 (48.8)
0.10–0.25 89 34 (38.2) 46 (51.7)
<0.10 61 16 (26.2) 0.9 25 (41.0) 0.65
HPV, human papillomavirus; HR, high risk; SHCS, Swiss HIV Cohort Study.
aAny HPV-L1: seropositivity of at least one HPV type among HPV16, 18, 31, 33, 35, 45, 52 and 58.
bCochran–Armitage trend test used for ordinal categories, x2 test for dichotomous categories.
cAsked to SHCS participants at follow-up visits after April 2000 only (n¼76).
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to improve the ability of HPV16-L1 and E6 antibody
status to discriminate future anal cancer risk.
Increases in seroprevalence and mean MFI values were
observed for all eight evaluated high-risk HPV-L1
antibodies. Seroconversion rates were far above those
of seroreversion and so could not be explained by random
fluctuation of test results around the cutoffs of the
serology assay, nor by high natural turnover of HPV
antibody responses. Furthermore, although we con-
firmed an association of recent sexual intercourse with
HPV seropositivity [6,9,26,27], HAART initiation did
not appear to increase risky sexual behavior (46.1%
declaring occasional partners at HAART initiation versus
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Table 2. Changes in human papillomavirus antibody seropositivity at HAART initiation and 24-month follow-up in 281 MSM.
Pos at HAART
initiation
Pos at 24-month
follow-up Prevalence ratio
(95% CI)
Status at both time points
n/total (%) n/total (%) þ/þ þ/ /þ /
HPV16-L1 91/281 (32.4) 135/281 (48.0) 1.48 (1.20–1.83) 80 (28.5) 11 (3.9) 55 (19.6) 135 (48.0)
HPV18 L1 35/281 (12.5) 76/281 (27.1) 2.17 (1.51–3.13) 28 (10.0) 7 (2.5) 48 (17.1) 198 (70.5)
HPV31 L1 50/281 (17.8) 97/281 (34.5) 1.94 (1.44–2.61) 45 (16.0) 5 (1.8) 52 (18.5) 179 (63.7)
HPV33 L1 27/281 (9.6) 55/281 (19.6) 2.04 (1.33–3.13) 24 (8.5) 3 (1.1) 31 (11.0) 223 (79.4)
HPV35 L1 44/281 (15.7) 72/281 (25.6) 1.64 (1.17–2.29) 41 (14.6) 3 (1.1) 31 (11.0) 206 (73.3)
HPV45 L1 31/281 (11.0) 83/281 (29.5) 2.68 (1.83–3.91) 25 (8.9) 6 (2.1) 58 (20.6) 192 (68.3)
HPV52 L1 36/281 (12.8) 64/281 (22.8) 1.78 (1.22–2.58) 31 (11.0) 5 (1.8) 33 (11.7) 212 (75.4)
HPV58 L1 22/281 (7.8) 40/28 (14.2) 1.82 (1.11–2.98) 19 (6.8) 3 (1.1) 21 (7.5) 238 (84.7)
Any HR-HPV-L1a 127/281 (45.2) 170/281 (60.5) 1.34 (1.14–1.57) 116 (41.3) 11 (3.9) 54 (19.2) 100 (35.6)
HPV6 L1 113/281 (40.2) 149/281 (53.0) 1.32 (1.10–1.58) 96 (34.2) 17 (6.1) 53 (18.9) 115 (40.9)
HPV11 L1 82/281 (29.2) 128/281 (45.6) 1.56 (1.25–1.95) 73 (26.0) 9 (3.2) 55 (19.6) 144 (51.3)
HPV16-E6 1/281 (0.4) 3/281 (1.1) 3.00 (0.31–28.7) 1 (0.4) 0 (0.0) 2 (0.7) 278 (98.9)
CI, confidence interval; HPV, human papillomavirus.
aAny HPV-L1: seropositivity of at least one HPV type among HPV16, 18, 31, 33, 35, 45, 52 and 58.
Table 3. Factors associated with seroconversiona after 24 months among patients human papillomavirus-L1-seronegative at HAART initiation.
HPV16-L1 Any HR-HPV-L1b
n (%) OR (95% CI) P trend n (%) OR (95% CI) P trend
Age (years)
45 15/53 (28.3) 1 29/78 (37.2) 1
35–44 21/66 (31.8) 1.16 (0.53–2.55) 45/100 (45.0) 1.38 (0.75–2.53)
<35 19/70 (27.1) 0.94 (0.43–2.09) 0.85 41/95 (43.2) 1.28 (0.70–2.37) 0.46
Tobacco
Ever 27/113 (23.9) 1 58/157 (36.9) 1
Never 27/75 (36.0) 1.79 (0.95–3.40) – 54/112 (48.2) 1.59 (0.97–2.60) –
History of AIDS
No 41/149 (27.5) 1 87/217 (40.1) 1
Yes 14/41 (34.2) 1.24 (0.75–2.04) – 28/56 (50.0) 1.49 (0.83–2.70) –
HIV viral load (copies/ml)
<10000 6/25 (24.0) 1 11/36 (30.6) 1
10000–99999 23/71 (32.4) 1.52 (0.53–4.31) 46/96 (47.9) 2.09 (0.93–4.72)
100000–499999 15/61 (24.6) 1.03 (0.35–3.06) 33/88 (37.5) 1.36 (0.59–3.13)
500000 9/26 (34.6) 1.68 (0.49–5.69) 0.78 22/45 (48.9) 2.17 (0.87–5.45) 0.42
CD4þ cell count (cells/ml)
350 7/46 (15.2) 1 19/65 (29.2) 1
200–350 13/47 (27.7) 2.13 (0.76–5.95) 26/70 (37.1) 1.43 (0.70–2.94)
50–199 17/60 (28.3) 2.20 (0.83–5.88) 41/89 (46.1) 2.07 (1.05–4.07)
<50 18/37 (48.7) 5.28 (1.88–14.8) <0.01 29/49 (59.2) 3.51 (1.61–7.67) <0.01
CD8þ cell count (cells/ml)
1000 14/54 (25.9) 1 36/85 (42.4) 1
750–999 16/44 (36.4) 1.63 (0.69–3.88) 28/58 (48.3) 1.27 (0.65–2.49)
500–749 10/45 (22.2) 0.82 (0.32–2.07) 22/64 (34.4) 0.71 (0.36–1.40)
<500 15/47 (31.9) 1.34 (0.56–3.18) 0.85 29/66 (43.9) 1.07 (0.56–2.04) 0.77
CD4þ/CD8þ ratio
0.5 4/34 (11.8) 1 12/45 (26.7) 1
0.25–0.49 13/52 (25.0) 2.50 (0.74–8.45) 31/79 (39.2) 1.78 (0.80–3.95)
0.10–0.24 16/55 (29.1) 3.08 (0.93–10.16) 37/84 (44.1) 2.16 (0.98–4.76)
<0.10 21/45 (46.7) 6.56 (1.98–21.71) <0.01 34/61 (55.7) 3.46 (1.51–7.96) <0.01
CI, confidence interval; HPV, human papillomavirus; HR, high risk; OR, odds ratio.
aSeroconversion¼ seroconversion of at least one HPV type.
bFor any HPV-L1: seronegative¼ seronegative for at least one HPV type among HPV16, 18, 31, 33, 35, 45, 52 and 58.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
38.4% at 24-month follow-up; data not shown) and
hence should also not explain high seroconversion rates.
The fact that seroconversion and MFI increases were
associated with lower CD4þ cell count and/or CD4þ/
CD8þ ratio pre-HAARTwould suggest that increases in
measurable HPV antibodies are principally due to
immune reconstitution, rather than exposure to new
HPV infections.
In contrast to the effect of low CD4þ cell count on
seroconversion and increases in L1 antibody titers, CD4þ
cell counts were not associated with cross-sectional
seroprevalence. This corroborates lack of association of
CD4þ cell counts with HPV seroprevalence in other
HIV-positive MSM [6,7,9] and HIV-positive women [28]
and suggests that HAART-related increases in detectable
HPV immune responses are not mediated solely via
CD4þ cell counts. Indeed, we have described a similar
phenomenon for Kaposi’s sarcoma-associated herpesvirus
antibodies in these samples [18].
High type-specific seroprevalences observed in the SHCS
are consistent with those reported in other HIV-positive
MSM [6,7,9,27], albeit with different serological assays.
Based on the same assay and cutoff definition, HPV6
(53%) and 11 (46%) seroprevalence in the SHCS was
similar to that reported in 245 HIV-positive MSM in
Australia (53 and 48%) [8]. HPV6 and 11 seroincidence,
on the other hand, was much higher in the current study
(12 and 11 per 100 person-years, calculated using
comparable criteria, versus 2.4 and 1.5 per 100 person-
years) [8], supporting the theory that HAART initiation is
a moment particularly disposed to HPV seroconversion.
HPV-L1 seroprevalence is higher in HIV-positive than
HIV-negative MSM [6,27]. This is expected to be related
to their higher prevalence of anal HPV infection [1,29],
known to be an important determinant of seropositivity
in MSM [9,29]. Our data, however, confirm that anal
HPVexposure is not sufficient for seroconversion in HIV-
positive MSM and could explain why anal HPV infection
was a significant determinant of HPV seroconversion in
HIV-negative, but not HIV-positive, MSM [6] in a cross-
sectional comparison that did not take HAART
into account.
HPV-L1 antibodies acquired through natural infection
have been shown to provide modest protection against
subsequent HPV infection in female patients, but not in
men [30]. This question requires data from large
prospective studies with multiple visits, because detect-
able L1 antibodies are also a marker of exposure and are
positively associated with HPV-related cancer [10,11,13–
16]. Indeed, in the present study, all anal cancers occurred
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Fig. 1. Mean change in human papillomavirus–L1 antibody response stratified by human papillomavirus type (a) and in human
papillomavirus 16-L1 by CD4R cell count (b).
Table 4. Anal cancer incidence according to human papillomavirus 16-L1 and E6 serology status post-HAART.
n Person-years Anal cancers Incidence rate (/100000) Incidence rate ratio
HPV16-L1 Negative 146 1685 0 0 1
Positive 133 1528 3 196 (63–609) 1 (0.5–1)
HPV16-E6 Negative 276 3187 2 63 (16–254) 1
Positive 3 25 1 3956 (557–28086) 63.1 (1.1–1211)
HPV, human papillomavirus.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
in MSM who were HPV16-L1-seropositive post-
HAART.
HPV vaccination results in far greater seroconversion
rates and antibody titers than natural HPV infection.
Interestingly, in two studies of quadrivalent HPV vaccine
of immunogenicity among HIV-infected men [31] and
women [32], no relationships between HPV antibody
concentrations and CD4þ cell counts were observed, but
higher antibody concentrations were reported in
HAARTusers. This suggests that the CD4þ-independent
effect of HAART on immune response that we have
described in the SHCS for natural HPV infection may
also play a role in vaccine-induced HPV antibody
response, even if the clinical significance of lower L1
antibody concentrations remains unknown because there
is no established threshold correlating with protection.
HPV16-E6 antibodies have already been shown to be
specific, but insensitive, markers of cervical [12] and anal
[10] cancer in the SHCS, but the present study is the first
to provide prospective data on the meaning of HPV16-E6
antibodies for future risk of HPV-related cancer in HIV-
positive populations. In our study of HIV-positive MSM,
only one patient (0.4%) was HPV16-E6-seropositive at
HAART initiation and remained cancer-free during his
entire 15-year follow-up. Two more HPV16-E6-ser-
opositive cases were revealed post-HAART, however, of
which one developed anal cancer 11 years later, so that
HPV16-E6 positivity post-HAARTwas associated with a
63-fold significant increase in anal cancer incidence,
albeit with very wide 95% CIs. Two out of the three anal
cancers were E6-seronegative, however, confirming
observations in the general (30% of anal cancers E6-
seropositive [15]) and HIV-positive (22% [10]) population
of a low sensitivity of HPV16-E6 antibody for predicting
anal cancer.
The principal novelty of our study design is represented
by samples selected at a 2-year interval pre-HAART and
post-HAART in a large and well characterized group of
HIV-positive MSM. Indeed, this set of samples has been
previously used to describe the effect of HAART on
Kaposi’s sarcoma-associated herpesvirus viremia and
antibodies [18]. In addition, however, 15-year follow-
up, during which time the SHCS has been regularly
linked with cancer registries [3,20], allowed an ad-hoc
cohort analysis of HPV-related cancer risk. Despite small
absolute numbers, high anal cancer incidence rates
(132 per 100 000 person-years) were comparable with
other estimates in HIV-positive MSM in the HAARTera
(131 per 100 000 person-years [4]) and enabled us to
identify significant serological determinants (HPV16-E6)
of anal cancer risk. Of note, the absence of other HPV-
related cancer diagnoses is consistent with the estimation
that anal cancer accounts for 85% of HPV-related cancers
in HIV-infected populations [33]. Other study limitations
include the lack of control group of HIVþMSM against
which to compare 2-year HPV seroconversion (e.g. naive
or long-term HAART users) and the unavailability of a
measure of HPV DNA, particularly from the anus, that
prevented us from distinguishing seropositivity related to
past or present infections. Although we had L1 serological
assays for only eight of the 12 HPV types that have been
designated as high-risk based on their carcinogenicity at
the cervix, and only HPV16-E6, HPV16 is the only HPV
type established as a cause of anal cancer [34], and is by
far the predominantly detected type in large cases series
of anal cancer [2,35], including those diagnosed
among HIV-positive persons [36,37]. In addition, there
is evidence for some cross-reactivity of HPV E6, but not
L1, assay antigens, for antibodies of closely phylogeneti-
cally related types [13].
With respect to estimating the fraction of HIV-positive
MSM who may profit from primary anal cancer
prevention by prophylactic HPV vaccination, we show
that seropositivity against HPV16 and other high-risk
HPV types is already very high in HAART-naive HIV-
infected MSM and that HAART reveals previously
undetectable antibody responses in an additional fraction.
This adds to evidence that not all anal HPV infections
result in detectable immune responses [6,7], so that a
definition of HPV seronegativity overestimates the truly
HPV-naive population. With respect to secondary anal
cancer prevention, our results suggest that HPV16-E6
antibodies might have some predictive value for risk
stratification of HIV-positive MSM, at least among those
commencing HAART. However, these findings remain
preliminary, and there remains little consensus about the
utility and/or the appropriate algorithm for further
diagnostic work-up and treatment.
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